慢性骨髄性白血病治療法の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Targeted therapy – Market size and forecast 2018-2023
• Chemotherapy – Market size and forecast 2018-2023
• Immunotherapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Emergence of pipeline molecules
• Development of diagnostic tests and predictive markers
• Increasing research in regenerative medicines
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Mylan NV
• Novartis AG
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 14: EXPLORE TECHNAVIO

Exhibit 01: Vendors: Key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Chemotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Chemotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Immunotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Immunotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Boehringer Ingelheim International GmbH – Vendor overview
Exhibit 51: Boehringer Ingelheim International GmbH – Product segments
Exhibit 52: Boehringer Ingelheim International GmbH – Organizational developments
Exhibit 53: Boehringer Ingelheim International GmbH – Geographic focus
Exhibit 54: Boehringer Ingelheim International GmbH – Segment focus
Exhibit 55: Boehringer Ingelheim International GmbH – Key offerings
Exhibit 56: Boehringer Ingelheim International GmbH – Key customers
Exhibit 57: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 58: Bristol-Myers Squibb Co. – Product segments
Exhibit 59: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 60: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 61: Bristol-Myers Squibb Co. – Key offerings
Exhibit 62: Bristol-Myers Squibb Co. – Key customers
Exhibit 63: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 64: F. Hoffmann-La Roche Ltd. – Product segments
Exhibit 65: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 66: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 67: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 68: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 69: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 70: Merck & Co. Inc. – Vendor overview
Exhibit 71: Merck & Co. Inc. – Product segments
Exhibit 72: Merck & Co. Inc. – Organizational developments
Exhibit 73: Merck & Co. Inc. – Geographic focus
Exhibit 74: Merck & Co. Inc. – Segment focus
Exhibit 75: Merck & Co. Inc. – Key offerings
Exhibit 76: Merck & Co. Inc. – Key customers
Exhibit 77: Mylan NV – Vendor overview
Exhibit 78: Mylan NV – Product segments
Exhibit 79: Mylan NV – Organizational developments
Exhibit 80: Mylan NV – Geographic focus
Exhibit 81: Mylan NV – Segment focus
Exhibit 82: Mylan NV – Key offerings
Exhibit 83: Mylan NV – Key customers
Exhibit 84: Novartis AG – Vendor overview
Exhibit 85: Novartis AG – Product segments
Exhibit 86: Novartis AG – Organizational developments
Exhibit 87: Novartis AG – Geographic focus
Exhibit 88: Novartis AG – Segment focus
Exhibit 89: Novartis AG – Key offerings
Exhibit 90: Novartis AG – Key customers
Exhibit 91: Otsuka Holdings Co. Ltd. – Vendor overview
Exhibit 92: Otsuka Holdings Co. Ltd. – Product segments
Exhibit 93: Otsuka Holdings Co. Ltd. – Organizational developments
Exhibit 94: Otsuka Holdings Co. Ltd. – Geographic focus
Exhibit 95: Otsuka Holdings Co. Ltd. – Segment focus
Exhibit 96: Otsuka Holdings Co. Ltd. – Key offerings
Exhibit 97: Otsuka Holdings Co. Ltd. – Key customers
Exhibit 98: Pfizer Inc. – Vendor overview
Exhibit 99: Pfizer Inc. – Product segments
Exhibit 100: Pfizer Inc. – Organizational developments
Exhibit 101: Pfizer Inc. – Geographic focus
Exhibit 102: Pfizer Inc. – Segment focus
Exhibit 103: Pfizer Inc. – Key offerings
Exhibit 104: Pfizer Inc. – Key customers
Exhibit 105: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 106: Takeda Pharmaceutical Co. Ltd. – Product segments
Exhibit 107: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 108: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 109: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 110: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 111: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 112: Teva Pharmaceutical Industries Ltd. – Product segments
Exhibit 113: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 114: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 115 Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 116: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 117: Validation techniques employed for market sizing
Exhibit 118: Definition of market positioning of vendors


【レポート販売概要】

■ タイトル:慢性骨髄性白血病治療法の世界市場2019-2023
■ 英文:Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
■ 発行日:2019年8月28日
■ 調査会社:Technavio
■ 商品コード:IRTNTR31940
■ 調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。